SYNLAB AGINH O.N. news, videos and press releases
For more news please use our advanced search feature.
SYNLAB AGINH O.N. - More news...
SYNLAB AGINH O.N. - More news...
- EQS-News: SYNLAB delivers strong performance in Q1 2024
- EQS-News: SYNLAB Italy has restored operations after cyber-attack
- EQS-Adhoc: SYNLAB AG: SYNLAB affected by cyber-attack in Italy
- EQS-News: SYNLAB delivers robust performance in FY 2023
- EQS-News: Continued strong performance in the third quarter of 2023
- EQS-News: SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven
- SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B
- EQS-News: SYNLAB AG: SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven
- EQS-Adhoc: SYNLAB AG: Cinven announces public acquisition offer | Conclusion of Investment Agreement
- EQS-WpÜG: Tender Offer / Target company: SYNLAB AG; Bidder: Ephios Luxembourg S.à r.l.
- EQS-News: SYNLAB AG: SYNLAB agrees to sell its veterinary diagnostics business to Mars
- EQS-News: SYNLAB AG: Continued strong performance in the second quarter of 2023
- EQS-News: SYNLAB AG: SYNLAB plays key role in the largest ever multinational study on cholesterol
- EQS-News: SYNLAB AG: SYNLAB invests in innovative Healthcare Centre in Florence
- EQS-News: SYNLAB AG: SYNLAB agrees to sell Swiss business to Sonic Healthcare
- EQS-News: SYNLAB AG: SYNLAB reports strong start to fiscal year 2023
- EQS-News: SYNLAB AG: SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region
- EQS-News: SYNLAB AG: SYNLAB delivers robust underlying growth in FY 2022
- EQS-Adhoc: SYNLAB AG: Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO
- EQS-Adhoc: SYNLAB AG: Non-binding expression of interest by Cinven for acquisition offer at an indicative offer price of 10.00 Euro per SYNLAB share
- EQS-News: SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing
- EQS-Adhoc: SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes
- EQS-News: SYNLAB AG: Portuguese competition authority investigating the local laboratory diagnostics market – SYNLAB’s operations in Portugal included in such investigation
- EQS-Adhoc: SYNLAB AG: Proceedings of the Portuguese Competition Authority against entities of SYNLAB
- EQS-News: SYNLAB AG: SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance
- EQS-News: SYNLAB AG: SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
- DGAP-News: SYNLAB reports solid H1 2022 results and raises 2022 revenue guidance
- DGAP-News: SYNLAB reports a strong start to the fiscal year 2022
- DGAP-News: SYNLAB AG: SYNLAB Medical Congress: making healthcare future-proof with advanced diagnostics
- DGAP-News: Disclosure on share buy-back according to Article 2 (1) of the Delegated Regulation (EU) No. 2016/1052 and Article 5 (1) Regulation (EU) No 2014/596 (Market Abuse Regulation)